Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Eli Lilly

Pfizer

A few big biopharma names were on the move Tuesday morning, and analysts are taking their shot at them.

3 Big Biopharma Stocks to Watch on Tuesday

THOUSAND OAKS, Calif., Feb. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today outlined its growth strategy through 2030, a period during which the Company expects to deliver attractive financial performance by serving many more patients globally than it does today, both with its current portfolio of marketed medicines and with the numerous new medicines it is advancing through its pipeline.

AMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT VIRTUAL BUSINESS REVIEW

Shares of Amgen Inc. AMGN, +5.30% shot up 5.2% in morning trading Tuesday, enough to pace the Dow Jones Industrial Average's DJIA, +0.31% gainers, after the biotechnology company provided a mixed full-year outlook but said it would buy back up to $6 billion worth of stock in the current quarter. The company said it expects 2022 adjusted earnings per share of $17.00 to $18.00, which surrounds the FactSet consensus of $17.65.

Amgen's stock surges to pace the Dow's gainers after plans to buy back up to $6 billion of its shares this quarter

THOUSAND OAKS, Calif., Feb. 8, 2022 /PRNewswire/ -- In connection with its virtual business review, Amgen (NASDAQ:AMGN) provided preliminary long-term guidance between 2022 and 2030 in addition to full year 2022 guidance.

AMGEN PROVIDES LONG-TERM GUIDANCE THROUGH 2030 DURING BUSINESS REVIEW MEETING

Clorox

Campbell Soup

Enterprise Products Partners

Lazard

Magellan Midstream Partners

Verizon

If any investor has stood the test of time, it is Warren Buffett. For years, the “Oracle of Omaha” has had a rock-star-like presence in the investing world His annual Berkshire Hathaway shareholders meeting draws thousands of loyal fans that are investors in the fund.

Warren Buffet's 8 Highest Yielding Stocks Also May Be Incredible 2022 Bargains

Amgen Inc's  AMGN Q4 revenues increased 3% Y/Y to $6.84 billion, slightly missing the consensus of $6.88 billion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Amgen's Q4 Sales Remain Flat As Its Biggest Product Flounders

Chegg

Take-Two Interactive Software

After Monday's close, more companies reported earnings results, including Amgen, TakeTwo Interactive and Chegg.

Mixed Earnings Results for Amgen, TakeTwo; Chegg Jumps on Beat

Amgen (AMGN) delivered earnings and revenue surprises of 5.31% and 0.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Beats Q4 Earnings Estimates

Shares of Amgen Inc. (NASDAQ: AMGN) stepped higher following the release of its Q4 earnings report showing an EPS beat and a slight miss on sales. The company reported, on a GAAP basis, a 2% decrease year-over-year in total operating expenses with a full year increase of 13% “primarily driven by the acquisition of Five Prime Therapeutics.

What's Going On With Amgen Stock During Today's After-Hours Session

Shares of Amgen Inc. AMGN, +0.64% rose more than 3% in the extended session Monday after the drug maker reported an adjusted quarterly profit above Wall Street expectations and said sales rose in part due to COVID-19 products. Amgen said it earned $1.9 billion, or $3.36 a share, in the quarter, compared with $1.6 billion, or $2.76 a share, in the year-ago quarter.

Amgen stock rises after COVID drugs boost Q4 profit

THOUSAND OAKS, Calif., Feb. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020.

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS

Amgen (NASDAQ: AMGN) will announce fourth-quarter earnings results this Monday, February 07, after the market closes. Amgen shares have weakened slightly above 1% since the beginning of the 2022 year, and the current price stands at $222.11.

Amgen price outlook ahead of FQ4 earnings

Adicet Bio, Inc.

AstraZeneca

These companies' share prices could rise in the short term, but their long-term opportunities are even better.

3 Biotech Stocks That Could Make You Richer in February (and Beyond)

Simon Property Group

Tenet Healthcare

While not quite the shock that Meta Platforms sprung on Wednesday, two companies that reported after markets closed Thursday have reversed the sentiment that prevailed.

Earnings Previews: Amgen, Simon Property, Tenet Healthcare

THOUSAND OAKS, Calif., Feb. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a virtual Business Review Meeting at 8:00 a.m.

AMGEN TO HOST VIRTUAL BUSINESS REVIEW MEETING

THOUSAND OAKS, Calif. and SAN DIEGO, Feb. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics toward historically challenging drug targets.

AMGEN AND PLEXIUM ANNOUNCE MULTI-YEAR, DRUG DISCOVERY COLLABORATION TO IDENTIFY NOVEL TARGETED PROTEIN DEGRADATION THERAPIES

Best Buy

Morgan Stanley

Restaurant Brands

Royal Bank of Canada

Snap-on

Toronto-Dominion Bank

T. Rowe Price Group

U.S. Bancorp

I present my top 10 High Yield dividend stocks that are poised to offer strong future returns. The annualized rate of return for this watchlist is 40.16% over the past 15 months.

My Top 10 High Yield Dividend Stocks For February 2022

Bristol-Myers

Gilead Sciences

Biotech's blue bloods are the best bets in the space right now.

How to Invest in Biotech When Deep Value Has no Discernible Meaning

Boeing

Disney

Merck

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Just because a company is a massive household name doesn't always mean investors should jump in after its stock takes a sizable dip.

Are the Dow's Worst-Performing Stocks of 2021 Ready to Rebound in 2022?

Baxter

Blackrock Inc

Intel

Lockheed Martin

Medtronic

Northrop Grumman

Oracle

Roper Technologies

I rank a selection of dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. To pick candidates, I use different screens every month that focus on various aspects of dividend growth investing such as valuation, yield, and growth.

10 Dividend Growth Stocks For January 2022

The big question is, can they continue to increase them?

2 High-Yielding Dividend Stocks That Have Doubled Their Payouts in 7 Years

Is Amgen (AMGN) a great pick from the value investor's perspective right now? Read on to know more.

Can Value Investors Select Amgen (AMGN) Stock Now?

In the latest trading session, Amgen (AMGN) closed at $224, marking a +0.66% move from the previous day.

Amgen (AMGN) Gains As Market Dips: What You Should Know

Earlier this month, the European Commission gave Lumykras the go-ahead as a treatment for lung cancer.

Amgen Wins Another Key Approval for This Potential Blockbuster Cancer Drug

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Amgen Stock (AMGN)